Business Context and Reporting Period
Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms. The company operates as a stand-alone entity following a separation and distribution from its former parent in May 2024, which transferred the INBRX-101 asset to an acquirer (Aventis Inc., a subsidiary of Sanofi). This Form 10-Q covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1.3 million | $0.1 million |
| Net Loss | $(35.3) million | $(43.9) million | $(107.2) million | $1,735.4 million (Income) |
| Operating Expenses | $33.8 million | $46.8 million | $105.4 million | $281.6 million |
| Cash and Equivalents | $153.1 million (as of Sept 30, 2025) | |||
| Long-Term Debt | $99.9 million (net of discount) | |||
| Accumulated Deficit | $213.4 million (as of Sept 30, 2025) |
Note: YTD 2024 net income was driven by a $2.0 billion non-cash gain related to the transaction with the Acquirer.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by 28% in Q3 2025 compared to Q3 2024 ($33.8M vs. $46.8M) and by 63% on a YTD basis ($105.4M vs. $281.6M). The YTD decrease is largely attributable to the absence of $68.1 million in merger-related costs and significant stock-based compensation acceleration ($41.1 million) recognized in 2024 upon the separation.
- Debt Structure: The company extinguished its prior $200 million debt obligation in May 2024 when it was assumed by the Acquirer. In January 2025, Inhibrx entered a new $100 million loan agreement with Oxford Finance, resulting in interest expense of $3.2 million in Q3 2025, compared to zero in Q3 2024.
- Revenue: YTD 2025 revenue of $1.3 million stems from a license agreement with Scithera, Inc., recognized in Q2 2025. No revenue was recognized in Q3 2025.
Outlook, Risks, and Management Commentary
- Clinical Pipeline Progress:
- Ozekibart (INBRX-109): In October 2025, the company announced that its Phase 2 trial in chondrosarcoma met its primary endpoint, demonstrating a 52% reduction in the risk of disease progression or death. A Biologics License Application (BLA) is planned for submission in Q2 2026. Interim data in colorectal cancer and Ewing sarcoma also showed positive response rates.
- INBRX-106: Phase 2 data in head and neck squamous cell carcinoma (HNSCC) is expected in Q4 2025. Positive results would ungate a Phase 3 trial.
- Liquidity: Management believes existing cash of $153.1 million is sufficient to fund operations for at least 12 months. The company may seek additional capital through equity, debt, or strategic collaborations.
- Risks: The company is exploring alternatives to monetize ozekibart (INBRX-109). Management warns that failure to consummate a transaction, or delays in doing so, could negatively impact stock price and operations. Additionally, the company relies on third-party manufacturers and faces standard biotech development risks regarding clinical trial outcomes and regulatory approvals.
Investor Verification Checklist
- Cash Runway: Verify the $153.1 million cash balance against the projected burn rate to confirm the 12-month liquidity runway.
- Debt Covenants: Review the terms of the 2025 Loan Agreement, specifically the interest-only period ending February 2028 and the 9% final payment fee.
- BLA Timeline: Monitor the progress toward the planned Q2 2026 submission of the Biologics License Application for ozekibart in chondrosarcoma.
- Monetization Strategy: Track updates regarding potential strategic transactions or partnerships for the ozekibart asset, as noted in the risk factors.
- Phase 2 Data Readout: Confirm the release of INBRX-106 Phase 2 data in HNSCC expected in Q4 2025.